Latest On Travere Therapeutics, Inc (RTRX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2020-11-17 18:33 EST | News | Retrophin rebrands itself as Travere Therapeutics | N/A |  |
| 2020-11-09 13:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-09 05:04 EST | Analyst Rating | The Analyst Target Price has increased from $30.75 to $31.38. | Buy | |
| 2020-11-08 13:41 EST | News | Retrophin's (RTRX) CEO Eric Dube on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-08 00:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 15:48 EST | News | Retrophin EPS beats by $0.07, beats on revenue | N/A | |
| 2020-11-06 21:24 EST | Insider Trade | STEVE ASELAGE has directly disposed of 20,625 shares and currently holds 213,107 shares. | Sell | |
| 2020-11-06 21:24 EST | Insider Trade | STEVE ASELAGE has directly disposed of 2,500 shares and currently holds 233,732 shares. | Sell | |
| 2020-11-06 12:40 EST | Earnings Estimate | An EPS average of -$0.66 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-10-30 14:33 EST | Analyst Rating | The Analyst Target Price has increased from $29.67 to $30.75. | Buy | |
| 2020-10-23 06:52 EST | News | Retrophin to buy Orphan Tech for $90M upfront | N/A | |
| 2020-10-05 20:43 EST | Insider Trade | Peter Heerma has directly disposed of 2,188 shares and currently holds 42,329 shares. | Sell | |
| 2020-10-05 20:43 EST | Insider Trade | Peter Heerma has directly disposed of 2,188 shares and currently holds 44,517 shares. | Sell | |
| 2020-09-26 13:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-23 20:12 EST | Insider Trade | Laura Clague has directly disposed of 1,500 shares and currently holds 19,473 shares. | Sell | |
| 2020-09-23 20:12 EST | Insider Trade | Noah L. Rosenberg has directly disposed of 750 shares and currently holds 27,555 shares. | Sell | |
| 2020-09-23 20:12 EST | Insider Trade | ELIZABETH E REED has directly disposed of 1,500 shares and currently holds 25,431 shares. | Sell | |
| 2020-09-23 20:12 EST | Insider Trade | WILLIAM E. ROTE has directly disposed of 1,500 shares and currently holds 24,086 shares. | Sell | |
| 2020-09-22 21:27 EST | Insider Trade | Eric M Dube has directly disposed of 1,565 shares and currently holds 94,695 shares. | Sell | |
| 2020-09-22 21:27 EST | Insider Trade | Eric M Dube has directly disposed of 9,240 shares and currently holds 96,260 shares. | Sell | |
| 2020-09-22 21:27 EST | Insider Trade | Eric M Dube has directly acquired 3,000 shares and currently holds 105,500 shares. | Buy | |
| 2020-09-22 21:27 EST | Insider Trade | Eric M Dube has directly acquired 25,000 shares and currently holds 102,500 shares. | Buy | |
| 2020-09-22 21:27 EST | Insider Trade | Laura Clague has directly disposed of 1,500 shares and currently holds 20,973 shares. | Sell | |
| 2020-09-22 21:27 EST | Insider Trade | Laura Clague has directly acquired 3,000 shares and currently holds 22,473 shares. | Buy | |
| 2020-09-22 21:27 EST | Insider Trade | ELIZABETH E REED has directly disposed of 1,500 shares and currently holds 26,931 shares. | Sell | |
| 2020-09-22 21:27 EST | Insider Trade | ELIZABETH E REED has directly acquired 3,000 shares and currently holds 28,431 shares. | Buy | |
| 2020-09-22 21:27 EST | Insider Trade | Noah L. Rosenberg has directly disposed of 750 shares and currently holds 28,305 shares. | Sell | |
| 2020-09-22 21:27 EST | Insider Trade | Noah L. Rosenberg has directly acquired 3,000 shares and currently holds 29,055 shares. | Buy | |
| 2020-09-22 21:27 EST | Insider Trade | WILLIAM E. ROTE has directly disposed of 1,500 shares and currently holds 25,586 shares. | Sell | |
| 2020-09-22 21:27 EST | Insider Trade | WILLIAM E. ROTE has directly acquired 3,000 shares and currently holds 27,086 shares. | Buy | |
| 2020-09-22 06:56 EST | News | Retrophin enrolls patients for the study of sparsentan in IgA nephropathy | N/A | |
| 2020-09-18 13:32 EST | Analyst Rating | The Analyst Target Price has increased from $29.25 to $29.67. | Buy | |
| 2020-09-17 06:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-01 21:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-27 09:31 EST | Analyst Rating | The Analyst Target Price has increased from $29.14 to $29.25. | Buy | |
| 2020-08-25 18:36 EST | News | BofA bullish on Retrophin, sees 56% upside | N/A | |
| 2020-08-14 10:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-08 01:59 EST | News | Retrophin (RTRX) Corporate Presentation - Slideshow | N/A | |
| 2020-08-06 21:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 17:14 EST | Insider Trade | STEVE ASELAGE has directly disposed of 2,500 shares and currently holds 236,232 shares. | Sell | |
| 2020-08-06 13:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-03 21:01 EST | News | Retrophin, Inc. (RTRX) CEO Eric Dube on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-08-03 09:32 EST | Analyst Rating | The Analyst Target Price has increased from $28.57 to $29.14. | Buy | |
| 2020-08-03 05:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-01 09:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:36 EST | News | Retrophin EPS beats by $0.14, beats on revenue | N/A | |
| 2020-07-31 02:11 EST | Analyst Rating | The Analyst Target Price has increased from $27.57 to $28.57. | Buy | |
| 2020-07-30 19:57 EST | Insider Trade | Noah L. Rosenberg has directly disposed of 870 shares and currently holds 26,055 shares. | Sell | |
| 2020-07-30 17:42 EST | Financials | Company financials have been released. | Neutral | |
About Travere Therapeutics, Inc (RTRX):
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
General
- Name Travere Therapeutics, Inc
- Symbol RTRX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 221
- Last Split Factor1:9
- Last Split Date2011-11-08
- Fiscal Year EndDecember
- IPO Date2012-11-08
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.retrophin.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 5.55
- Price/Book (Most Recent Quarter) 4.01
- Enterprise Value Revenue 4.98
View More
Financials
- Most Recent Quarter 2020-09-30
- Current Year EPS Estimate -$1.54
- Next Year EPS Estimate -$2.07
- Next Quarter EPS Estimate -$0.59
- Profit Margin -40%
- Operating Margin -36%
- Return on Assets -7%
- Return on Equity -29%
- Revenue 194.02 million
- Earnings Per Share -$3.42
- Revenue Per Share $4.27
- Gross Profit 170.1 million
- Quarterly Earnings Growth 15.2%
View More
Highlights
- Market Capitalization 1.24 billion
- EBITDA -76322000
- PEG Ratio -1.05
- Analyst Target Price $31.38
- Book Value Per Share $5.91
View More
Share Statistics
- Shares Outstanding 51.05 million
- Shares Float 42.53 million
- % Held by Insiders 90%
- % Held by Institutions 104.8%
- Shares Short 4.81 million
- Shares Short Prior Month 4.73 million
- Short Ratio 18.1
- Short % of Float 10%
- Short % of Shares Outstanding 9%
View More
Technicals
- Beta 0.72
- 52 Week High $25.5
- 52 Week Low $8.98
- 50 Day Moving Average 21.38
- 200 Day Moving Average 19.02
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
View More
Travere Therapeutics, Inc (RTRX) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Travere Therapeutics, Inc (RTRX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-05 | $N/A | -$0.44 | -$0.52 | 15.38% |
| 2020-06-30 | 2020-07-30 | $N/A | -$0.58 | -$0.56 | -3.57% |
| 2020-03-31 | 2020-05-11 | $47.77 million | $0.02 | -$0.67 | 102.99% |
| 2019-12-31 | 2020-02-24 | $46.69 million | -$0.70 | -$0.64 | -9.38% |
| 2019-09-30 | 2019-10-30 | $44.37 million | -$0.85 | -$1.05 | 19.05% |
| 2019-06-30 | 2019-08-06 | $44.71 million | -$0.92 | -$0.64 | -43.75% |
| 2019-03-31 | 2019-05-07 | $39.57 million | -$0.99 | -$0.57 | -73.68% |
| 2018-12-31 | 2019-02-26 | $43.77 million | -$0.18 | -$0.48 | 62.5% |
| 2018-09-30 | 2018-11-01 | $40.71 million | -$1.34 | -$0.45 | -197.78% |
| 2018-06-30 | 2018-07-26 | $41.34 million | -$0.56 | -$0.35 | -60% |
| 2018-03-31 | 2018-05-01 | $38.43 million | -$0.46 | -$0.45 | -2.22% |
| 2017-12-31 | 2018-02-27 | $42.18 million | -$0.45 | -$0.19 | -136.84% |
| 2017-09-30 | 2017-11-07 | $40.34 million | -$0.46 | -$0.25 | -84% |
| 2017-06-30 | 2017-08-09 | $38.8 million | -$0.34 | -$0.21 | -61.9% |
| 2017-03-31 | 2017-05-04 | $33.62 million | -$0.29 | -$0.26 | -11.54% |
| 2016-12-31 | 2017-03-01 | $37.33 million | -$0.23 | -$0.26 | 11.54% |
| 2016-09-30 | 2016-11-03 | $33.95 million | -$1.00 | $0.38 | -363.16% |
| 2016-06-30 | 2016-08-04 | $33.31 million | -$0.37 | -$0.23 | -60.87% |
| 2016-03-31 | 2016-05-03 | $29.01 million | $0.31 | -$0.22 | 240.91% |
| 2015-12-31 | 2016-02-25 | $30.45 million | -$0.07 | -$0.21 | 66.67% |
| 2015-09-30 | 2015-11-03 | $28 million | $1.78 | $1.65 | 7.88% |
| 2015-06-30 | 2015-08-04 | $24.07 million | -$0.73 | -$0.42 | -73.81% |
| 2015-03-31 | 2015-05-11 | $17.37 million | $1.32 | -$0.34 | 488.24% |
| 2014-12-31 | 2015-03-05 | $14.09 million | -$1.10 | ||
| 2014-09-30 | 2014-11-13 | $8.35 million | -$0.89 | ||
| 2014-06-30 | 2014-08-12 | $5.74 million | -$0.90 | ||
| 2014-03-31 | 2014-05-14 | $28000 | -$0.73 | -$0.44 | -65.91% |
| 2013-12-31 | 2014-03-27 | $N/A | -$0.76 | -$0.30 | -153.33% |
| 2013-09-30 | 2013-11-18 | $N/A | -$0.60 | -$0.18 | -233.33% |
| 2013-06-30 | 2013-08-28 | $N/A | -$0.41 | ||
| 2013-03-31 | 2013-05-29 | $N/A | -$0.44 | ||
| 2012-12-31 | 2012-12-31 | $N/A | -$8.28 | ||
| 2011-09-30 | 2011-11-30 | $N/A | $-0.00 | ||
| 2011-06-30 | 2011-08-31 | $N/A | -$0.03 | ||
| 2011-03-31 | 2011-05-31 | -$0.03 | |||
| 2010-12-31 | 2011-02-28 | -$0.04 | |||
| 2010-09-30 | 2010-11-30 | -$0.05 | |||
| 2010-06-30 | 2010-08-31 | -$0.06 | |||
| 2010-03-31 | 2010-05-31 | -$0.06 | |||
| 2009-12-31 | 2010-02-28 | -$0.07 | |||
| 2009-09-30 | 2009-11-30 | -$0.06 | |||
| 2009-06-30 | 2009-08-31 | -$0.06 | |||
| 2009-03-31 | 2009-05-31 | -$0.07 | |||
| 2008-12-31 | 2009-02-28 | -$0.07 | |||
| 2008-09-30 | 2008-11-30 | -$0.04 | |||
| 2008-06-30 | 2008-08-31 | -$0.03 | |||
| 2008-03-31 | 2008-05-31 | -$0.03 |
Travere Therapeutics, Inc (RTRX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Travere Therapeutics, Inc (RTRX) Chart:
Travere Therapeutics, Inc (RTRX) News:
Below you will find a list of latest news for Travere Therapeutics, Inc (RTRX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Travere Therapeutics, Inc (RTRX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Travere Therapeutics, Inc (RTRX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120039338/0001209191-20-039338-index.htm |
| 2020-09-04 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1438533/000000000020008369/0000000000-20-008369-index.htm |
| 2020-09-29 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1438533/000000000020009154/0000000000-20-009154-index.htm |
| 2019-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000021545719007297/0000215457-19-007297-index.htm |
| 2020-01-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000083423720000050/0000834237-20-000050-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000089109219001947/0000891092-19-001947-index.htm |
| 2019-08-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000089109219008367/0000891092-19-008367-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000089109220001777/0000891092-20-001777-index.htm |
| 2019-07-19 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000091957419004701/0000919574-19-004701-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000091957420001120/0000919574-20-001120-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000108514619000745/0001085146-19-000745-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000108514620000796/0001085146-20-000796-index.htm |
| 2020-02-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000110465920016391/0001104659-20-016391-index.htm |
| 2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000110465920021908/0001104659-20-021908-index.htm |
| 2020-02-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000114544320000118/0001145443-20-000118-index.htm |
| 2018-09-06 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1438533/000119312518268237/0001193125-18-268237-index.htm |
| 2018-09-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000119312518270154/0001193125-18-270154-index.htm |
| 2019-01-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000119312519001689/0001193125-19-001689-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000119312519003071/0001193125-19-003071-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000119312519040338/0001193125-19-040338-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000119312519040997/0001193125-19-040997-index.htm |
| 2019-04-04 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1438533/000119312519097950/0001193125-19-097950-index.htm |
| 2019-08-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000119312519226355/0001193125-19-226355-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000119312520005878/0001193125-20-005878-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000119312520034843/0001193125-20-034843-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000119312520038267/0001193125-20-038267-index.htm |
| 2020-02-24 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1438533/000119312520046689/0001193125-20-046689-index.htm |
| 2020-06-08 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1438533/000119312520163477/0001193125-20-163477-index.htm |
| 2020-06-09 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1438533/000119312520164634/0001193125-20-164634-index.htm |
| 2020-06-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000119312520164649/0001193125-20-164649-index.htm |
| 2020-09-21 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1438533/000119312520249779/0001193125-20-249779-index.htm |
| 2018-11-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118058647/0001209191-18-058647-index.htm |
| 2018-11-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118058648/0001209191-18-058648-index.htm |
| 2018-11-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118058649/0001209191-18-058649-index.htm |
| 2018-11-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118058650/0001209191-18-058650-index.htm |
| 2018-11-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118058651/0001209191-18-058651-index.htm |
| 2018-11-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059063/0001209191-18-059063-index.htm |
| 2018-11-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059064/0001209191-18-059064-index.htm |
| 2018-11-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059065/0001209191-18-059065-index.htm |
| 2018-11-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059066/0001209191-18-059066-index.htm |
| 2018-11-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059067/0001209191-18-059067-index.htm |
| 2018-12-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118061669/0001209191-18-061669-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118063772/0001209191-18-063772-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118063774/0001209191-18-063774-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118063776/0001209191-18-063776-index.htm |
| 2018-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118064021/0001209191-18-064021-index.htm |
| 2018-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118064022/0001209191-18-064022-index.htm |
| 2018-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919118064023/0001209191-18-064023-index.htm |
| 2019-01-08 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119002856/0001209191-19-002856-index.htm |
| 2019-01-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119002858/0001209191-19-002858-index.htm |
| 2019-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119003163/0001209191-19-003163-index.htm |
| 2019-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119009924/0001209191-19-009924-index.htm |
| 2019-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119009925/0001209191-19-009925-index.htm |
| 2019-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119009926/0001209191-19-009926-index.htm |
| 2019-02-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119009927/0001209191-19-009927-index.htm |
| 2019-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119011822/0001209191-19-011822-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029151/0001209191-19-029151-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029152/0001209191-19-029152-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029153/0001209191-19-029153-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029154/0001209191-19-029154-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029155/0001209191-19-029155-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029156/0001209191-19-029156-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029157/0001209191-19-029157-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029159/0001209191-19-029159-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029173/0001209191-19-029173-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029174/0001209191-19-029174-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029175/0001209191-19-029175-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029176/0001209191-19-029176-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029177/0001209191-19-029177-index.htm |
| 2019-05-15 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030177/0001209191-19-030177-index.htm |
| 2019-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030178/0001209191-19-030178-index.htm |
| 2019-05-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030657/0001209191-19-030657-index.htm |
| 2019-05-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030658/0001209191-19-030658-index.htm |
| 2019-05-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030659/0001209191-19-030659-index.htm |
| 2019-05-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030660/0001209191-19-030660-index.htm |
| 2019-05-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030661/0001209191-19-030661-index.htm |
| 2019-07-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119043930/0001209191-19-043930-index.htm |
| 2019-10-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119051974/0001209191-19-051974-index.htm |
| 2019-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119051975/0001209191-19-051975-index.htm |
| 2019-11-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919119058446/0001209191-19-058446-index.htm |
| 2020-01-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120002631/0001209191-20-002631-index.htm |
| 2020-01-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120002635/0001209191-20-002635-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120005899/0001209191-20-005899-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120005900/0001209191-20-005900-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120005901/0001209191-20-005901-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120005903/0001209191-20-005903-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120005904/0001209191-20-005904-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120005905/0001209191-20-005905-index.htm |
| 2020-02-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120007720/0001209191-20-007720-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120010482/0001209191-20-010482-index.htm |
| 2020-03-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120017537/0001209191-20-017537-index.htm |
| 2020-03-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120017538/0001209191-20-017538-index.htm |
| 2020-03-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120017539/0001209191-20-017539-index.htm |
| 2020-03-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120017540/0001209191-20-017540-index.htm |
| 2020-03-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120017541/0001209191-20-017541-index.htm |
| 2020-03-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120018647/0001209191-20-018647-index.htm |
| 2020-03-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120018648/0001209191-20-018648-index.htm |
| 2020-03-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120018649/0001209191-20-018649-index.htm |
| 2020-04-09 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120024095/0001209191-20-024095-index.htm |
| 2020-04-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120024096/0001209191-20-024096-index.htm |
| 2020-05-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120027448/0001209191-20-027448-index.htm |
| 2020-05-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029021/0001209191-20-029021-index.htm |
| 2020-05-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029022/0001209191-20-029022-index.htm |
| 2020-05-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029023/0001209191-20-029023-index.htm |
| 2020-05-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029024/0001209191-20-029024-index.htm |
| 2020-05-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029410/0001209191-20-029410-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030743/0001209191-20-030743-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030744/0001209191-20-030744-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030745/0001209191-20-030745-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030746/0001209191-20-030746-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030747/0001209191-20-030747-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030748/0001209191-20-030748-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030749/0001209191-20-030749-index.htm |
| 2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030750/0001209191-20-030750-index.htm |
| 2020-06-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120039338/0001209191-20-039338-index.htm |
| 2020-07-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120044098/0001209191-20-044098-index.htm |
| 2020-08-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120045456/0001209191-20-045456-index.htm |
| 2020-09-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051611/0001209191-20-051611-index.htm |
| 2020-09-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051612/0001209191-20-051612-index.htm |
| 2020-09-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051613/0001209191-20-051613-index.htm |
| 2020-09-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051614/0001209191-20-051614-index.htm |
| 2020-09-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051615/0001209191-20-051615-index.htm |
| 2020-09-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051732/0001209191-20-051732-index.htm |
| 2020-09-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051734/0001209191-20-051734-index.htm |
| 2020-09-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051735/0001209191-20-051735-index.htm |
| 2020-09-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051736/0001209191-20-051736-index.htm |
| 2020-10-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120053925/0001209191-20-053925-index.htm |
| 2020-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1438533/000120919120057381/0001209191-20-057381-index.htm |
| 2020-01-28 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1438533/000131924420000022/0001319244-20-000022-index.htm |
| 2018-11-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853318000031/0001438533-18-000031-index.htm |
| 2018-11-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1438533/000143853318000032/0001438533-18-000032-index.htm |
| 2019-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000002/0001438533-19-000002-index.htm |
| 2019-02-26 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000003/0001438533-19-000003-index.htm |
| 2019-04-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000005/0001438533-19-000005-index.htm |
| 2019-04-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000007/0001438533-19-000007-index.htm |
| 2019-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000009/0001438533-19-000009-index.htm |
| 2019-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000011/0001438533-19-000011-index.htm |
| 2019-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000013/0001438533-19-000013-index.htm |
| 2019-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000016/0001438533-19-000016-index.htm |
| 2019-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000018/0001438533-19-000018-index.htm |
| 2019-07-26 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000020/0001438533-19-000020-index.htm |
| 2019-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000022/0001438533-19-000022-index.htm |
| 2019-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000024/0001438533-19-000024-index.htm |
| 2019-09-18 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000029/0001438533-19-000029-index.htm |
| 2019-10-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000032/0001438533-19-000032-index.htm |
| 2019-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000035/0001438533-19-000035-index.htm |
| 2019-10-30 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1438533/000143853319000036/0001438533-19-000036-index.htm |
| 2020-02-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000002/0001438533-20-000002-index.htm |
| 2020-02-24 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000004/0001438533-20-000004-index.htm |
| 2020-04-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000005/0001438533-20-000005-index.htm |
| 2020-04-14 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000007/0001438533-20-000007-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000009/0001438533-20-000009-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000011/0001438533-20-000011-index.htm |
| 2020-05-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000013/0001438533-20-000013-index.htm |
| 2020-06-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000015/0001438533-20-000015-index.htm |
| 2020-07-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000017/0001438533-20-000017-index.htm |
| 2020-07-31 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000020/0001438533-20-000020-index.htm |
| 2020-07-31 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000022/0001438533-20-000022-index.htm |
| 2020-10-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000024/0001438533-20-000024-index.htm |
| 2020-10-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000026/0001438533-20-000026-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000029/0001438533-20-000029-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1438533/000143853320000031/0001438533-20-000031-index.htm |
| 2019-06-07 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1438533/999999999719005380/9999999997-19-005380-index.htm |
Travere Therapeutics, Inc (RTRX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Travere Therapeutics, Inc (RTRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 90%Institutional Ownership: 10480%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-02-12 | Laura Clague | Chief Financial Officer | Sell | 1,016.00 | 21.50 | 21,844.00 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119009925/0001209191-19-009925-index.htm |
| 2020-09-18 | Eric M Dube | Chief Executive Officer | Buy | 25,000.00 | 102,500.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051611/0001209191-20-051611-index.htm | ||
| 2020-09-18 | Eric M Dube | Chief Executive Officer | Buy | 3,000.00 | 105,500.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051611/0001209191-20-051611-index.htm | ||
| 2019-05-08 | Roy D. Baynes | Director | Buy | 2,000.00 | 11,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029152/0001209191-19-029152-index.htm | ||
| 2019-02-11 | Laura Clague | Chief Financial Officer | Sell | 1,017.00 | 21.38 | 21,743.46 | 11,016.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119009925/0001209191-19-009925-index.htm |
| 2020-05-15 | John A Orwin | Director | Buy | 3,000.00 | 11,875.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030749/0001209191-20-030749-index.htm | ||
| 2020-05-15 | Ron Squarer | Director | Buy | 3,000.00 | 11,875.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030750/0001209191-20-030750-index.htm | ||
| 2018-11-15 | Laura Clague | Chief Financial Officer | Sell | 791.00 | 24.73 | 19,561.90 | 12,033.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059064/0001209191-18-059064-index.htm |
| 2018-12-21 | Laura Clague | Chief Financial Officer | Sell | 900.00 | 22.34 | 20,108.97 | 12,033.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118064021/0001209191-18-064021-index.htm |
| 2018-11-15 | Laura Clague | Chief Financial Officer | Sell | 2,959.00 | 24.20 | 71,605.14 | 12,824.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059064/0001209191-18-059064-index.htm |
| 2018-12-21 | Laura Clague | Chief Financial Officer | Sell | 2,850.00 | 21.67 | 61,751.24 | 12,933.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118064021/0001209191-18-064021-index.htm |
| 2019-05-16 | Laura Clague | Chief Financial Officer | Sell | 1,250.00 | 18.71 | 23,387.50 | 13,500.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030660/0001209191-19-030660-index.htm |
| 2019-07-31 | Noah L. Rosenberg | Chief Medical Officer | Sell | 1,250.00 | 20.07 | 25,087.50 | 13,500.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119043930/0001209191-19-043930-index.htm |
| 2019-02-19 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 1,250.00 | 21.52 | 26,900.00 | 13,810.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119011822/0001209191-19-011822-index.htm |
| 2020-05-15 | Roy D. Baynes | Director | Buy | 3,000.00 | 14,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030743/0001209191-20-030743-index.htm | ||
| 2019-02-12 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 884.00 | 21.50 | 19,006.00 | 14,558.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119009927/0001209191-19-009927-index.htm |
| 2019-05-15 | Laura Clague | Chief Financial Officer | Sell | 1,250.00 | 17.78 | 22,225.00 | 14,750.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030660/0001209191-19-030660-index.htm |
| 2019-07-30 | Noah L. Rosenberg | Chief Medical Officer | Sell | 1,250.00 | 19.82 | 24,775.00 | 14,750.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119043930/0001209191-19-043930-index.htm |
| 2019-02-15 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 1,250.00 | 21.44 | 26,800.00 | 15,060.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119011822/0001209191-19-011822-index.htm |
| 2019-02-11 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 885.00 | 21.38 | 18,921.30 | 15,442.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119009927/0001209191-19-009927-index.htm |
| 2018-11-14 | Laura Clague | Chief Financial Officer | Sell | 400.00 | 24.54 | 9,816.00 | 15,783.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059064/0001209191-18-059064-index.htm |
| 2018-12-20 | Laura Clague | Chief Financial Officer | Sell | 3,750.00 | 22.08 | 82,804.50 | 15,783.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118064021/0001209191-18-064021-index.htm |
| 2019-05-09 | Laura Clague | Chief Financial Officer | Buy | 6,000.00 | 16,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029174/0001209191-19-029174-index.htm | ||
| 2019-05-09 | Noah L. Rosenberg | Chief Medical Officer | Buy | 6,000.00 | 16,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029175/0001209191-19-029175-index.htm | ||
| 2019-02-12 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 992.00 | 21.50 | 21,328.00 | 16,007.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119009926/0001209191-19-009926-index.htm |
| 2018-11-14 | Laura Clague | Chief Financial Officer | Sell | 3,350.00 | 23.63 | 79,154.47 | 16,183.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059064/0001209191-18-059064-index.htm |
| 2019-01-09 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 750.00 | 23.82 | 17,865.00 | 16,327.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119003163/0001209191-19-003163-index.htm |
| 2019-02-11 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 993.00 | 21.38 | 21,230.34 | 16,999.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119009926/0001209191-19-009926-index.htm |
| 2019-01-08 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 750.00 | 24.09 | 18,067.50 | 17,077.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119003163/0001209191-19-003163-index.htm |
| 2018-11-15 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 100.00 | 24.81 | 2,480.50 | 17,827.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059066/0001209191-18-059066-index.htm |
| 2018-11-15 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 100.00 | 24.77 | 2,477.00 | 17,927.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059066/0001209191-18-059066-index.htm |
| 2018-11-15 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 312.00 | 24.83 | 7,745.87 | 17,992.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059065/0001209191-18-059065-index.htm |
| 2020-01-08 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 750.00 | 15.14 | 11,355.00 | 18,008.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120002635/0001209191-20-002635-index.htm |
| 2018-11-15 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 2,300.00 | 24.29 | 55,858.49 | 18,027.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059066/0001209191-18-059066-index.htm |
| 2019-05-15 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 812.00 | 17.76 | 14,421.12 | 18,185.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030659/0001209191-19-030659-index.htm |
| 2018-11-15 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 2,188.00 | 24.25 | 53,054.62 | 18,304.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059065/0001209191-18-059065-index.htm |
| 2020-01-07 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 750.00 | 13.94 | 10,455.00 | 18,758.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120002635/0001209191-20-002635-index.htm |
| 2019-05-14 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 813.00 | 17.78 | 14,455.14 | 18,997.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030659/0001209191-19-030659-index.htm |
| 2020-05-12 | Laura Clague | Chief Financial Officer | Sell | 527.00 | 16.98 | 8,950.73 | 19,473.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029022/0001209191-20-029022-index.htm |
| 2020-09-23 | Laura Clague | Chief Financial Officer | Sell | 1,500.00 | 18.48 | 27,720.00 | 19,473.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051732/0001209191-20-051732-index.htm |
| 2019-05-15 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 525.00 | 17.71 | 9,297.75 | 19,508.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030658/0001209191-19-030658-index.htm |
| 2018-11-09 | Laura Clague | Chief Financial Officer | Buy | 7,500.00 | 19,533.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118058648/0001209191-18-058648-index.htm | ||
| 2018-12-18 | Laura Clague | Chief Financial Officer | Buy | 7,500.00 | 19,533.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118063776/0001209191-18-063776-index.htm | ||
| 2019-05-09 | WILLIAM E. ROTE | Senior Vice President, R&D | Buy | 6,000.00 | 19,810.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029176/0001209191-19-029176-index.htm | ||
| 2020-05-12 | Laura Clague | Chief Financial Officer | Sell | 1,250.00 | 17.16 | 21,450.00 | 20,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029022/0001209191-20-029022-index.htm |
| 2019-05-14 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 525.00 | 17.75 | 9,318.75 | 20,033.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030658/0001209191-19-030658-index.htm |
| 2018-11-14 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 300.00 | 24.57 | 7,371.00 | 20,327.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059066/0001209191-18-059066-index.htm |
| 2018-11-14 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 300.00 | 24.57 | 7,371.00 | 20,492.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059065/0001209191-18-059065-index.htm |
| 2019-05-09 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Buy | 6,000.00 | 20,558.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029177/0001209191-19-029177-index.htm | ||
| 2018-11-14 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 2,200.00 | 23.62 | 51,958.94 | 20,627.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059066/0001209191-18-059066-index.htm |
| 2018-11-14 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 2,200.00 | 23.62 | 51,958.06 | 20,792.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059065/0001209191-18-059065-index.htm |
| 2020-09-22 | Laura Clague | Chief Financial Officer | Sell | 1,500.00 | 18.59 | 27,885.00 | 20,973.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051612/0001209191-20-051612-index.htm |
| 2020-05-11 | Laura Clague | Chief Financial Officer | Sell | 1,250.00 | 14.95 | 18,687.50 | 21,250.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029022/0001209191-20-029022-index.htm |
| 2020-11-06 | STEVE ASELAGE | Director | Sell | 20,625.00 | 23.00 | 474,375.00 | 213,107.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120057381/0001209191-20-057381-index.htm |
| 2020-09-18 | Laura Clague | Chief Financial Officer | Buy | 3,000.00 | 22,473.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051612/0001209191-20-051612-index.htm | ||
| 2020-01-31 | Laura Clague | Chief Financial Officer | Buy | 9,000.00 | 22,500.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120005900/0001209191-20-005900-index.htm | ||
| 2020-03-10 | Laura Clague | Chief Financial Officer | Sell | 4,000.00 | 15.02 | 60,080.00 | 22,500.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120018647/0001209191-20-018647-index.htm |
| 2020-01-31 | Noah L. Rosenberg | Chief Medical Officer | Buy | 9,000.00 | 22,500.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120005904/0001209191-20-005904-index.htm | ||
| 2018-11-09 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Buy | 5,000.00 | 22,827.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118058650/0001209191-18-058650-index.htm | ||
| 2018-11-09 | WILLIAM E. ROTE | Senior Vice President, R&D | Buy | 5,000.00 | 22,992.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118058651/0001209191-18-058651-index.htm | ||
| 2020-11-05 | STEVE ASELAGE | Director | Sell | 2,500.00 | 21.26 | 53,150.00 | 233,732.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120057381/0001209191-20-057381-index.htm |
| 2020-05-12 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 527.00 | 16.98 | 8,950.73 | 23,494.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029023/0001209191-20-029023-index.htm |
| 2020-08-05 | STEVE ASELAGE | Director | Sell | 2,500.00 | 19.68 | 49,200.00 | 236,232.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120045456/0001209191-20-045456-index.htm |
| 2020-06-25 | STEVE ASELAGE | Director | Sell | 10,000.00 | 20.00 | 200,000.00 | 238,732.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120039338/0001209191-20-039338-index.htm |
| 2020-05-12 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 812.00 | 17.16 | 13,933.92 | 24,021.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029023/0001209191-20-029023-index.htm |
| 2020-09-23 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 1,500.00 | 18.48 | 27,720.00 | 24,086.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051736/0001209191-20-051736-index.htm |
| 2020-05-14 | STEVE ASELAGE | Director | Sell | 3,062.00 | 15.09 | 46,205.58 | 245,732.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029410/0001209191-20-029410-index.htm |
| 2020-05-11 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 813.00 | 14.95 | 12,154.35 | 24,833.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029023/0001209191-20-029023-index.htm |
| 2020-02-05 | STEVE ASELAGE | Director | Sell | 2,500.00 | 16.62 | 41,550.00 | 248,466.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120007720/0001209191-20-007720-index.htm |
| 2020-05-15 | STEVE ASELAGE | Director | Buy | 3,000.00 | 248,732.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030744/0001209191-20-030744-index.htm | ||
| 2020-05-13 | STEVE ASELAGE | Director | Sell | 4,063.00 | 16.41 | 66,673.83 | 248,794.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029410/0001209191-20-029410-index.htm |
| 2019-11-29 | STEVE ASELAGE | Director | Sell | 5,000.00 | 13.91 | 69,552.50 | 250,966.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119058446/0001209191-19-058446-index.htm |
| 2018-12-07 | STEVE ASELAGE | Chief Executive Officer | Sell | 10.00 | 24.04 | 240.37 | 251,523.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118061669/0001209191-18-061669-index.htm |
| 2020-05-12 | STEVE ASELAGE | Director | Sell | 1,000.00 | 17.16 | 17,160.00 | 252,857.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029410/0001209191-20-029410-index.htm |
| 2018-11-15 | STEVE ASELAGE | Chief Executive Officer | Sell | 1,086.00 | 24.75 | 26,880.02 | 253,283.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059063/0001209191-18-059063-index.htm |
| 2020-05-05 | STEVE ASELAGE | Director | Sell | 2,500.00 | 15.88 | 39,700.00 | 253,857.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120027448/0001209191-20-027448-index.htm |
| 2020-05-12 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 527.00 | 16.98 | 8,950.73 | 25,431.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029024/0001209191-20-029024-index.htm |
| 2020-09-23 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 1,500.00 | 18.48 | 27,720.00 | 25,431.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051735/0001209191-20-051735-index.htm |
| 2018-11-15 | STEVE ASELAGE | Chief Executive Officer | Sell | 4,464.00 | 24.21 | 108,088.62 | 254,369.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059063/0001209191-18-059063-index.htm |
| 2020-09-22 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 1,500.00 | 18.59 | 27,885.00 | 25,586.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051615/0001209191-20-051615-index.htm |
| 2019-05-15 | STEVE ASELAGE | Director | Sell | 1,838.00 | 17.82 | 32,753.16 | 255,966.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030657/0001209191-19-030657-index.htm |
| 2020-03-05 | STEVE ASELAGE | Director | Sell | 4,359.00 | 15.36 | 66,938.55 | 256,357.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120017537/0001209191-20-017537-index.htm |
| 2020-02-18 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 1,250.00 | 16.55 | 20,687.50 | 25,646.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120010482/0001209191-20-010482-index.htm |
| 2020-03-10 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 3,250.00 | 14.87 | 48,327.50 | 25,646.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120018649/0001209191-20-018649-index.htm |
| 2019-02-12 | STEVE ASELAGE | Chief Executive Officer | Sell | 1,065.00 | 21.50 | 22,897.50 | 257,642.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119009924/0001209191-19-009924-index.htm |
| 2019-05-14 | STEVE ASELAGE | Director | Sell | 1,838.00 | 17.79 | 32,698.02 | 257,804.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030657/0001209191-19-030657-index.htm |
| 2019-02-11 | STEVE ASELAGE | Chief Executive Officer | Sell | 1,065.00 | 21.38 | 22,769.70 | 258,707.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119009924/0001209191-19-009924-index.htm |
| 2018-11-14 | STEVE ASELAGE | Chief Executive Officer | Sell | 600.00 | 24.58 | 14,745.00 | 258,833.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059063/0001209191-18-059063-index.htm |
| 2018-11-14 | STEVE ASELAGE | Chief Executive Officer | Sell | 4,950.00 | 23.63 | 116,989.79 | 259,433.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059063/0001209191-18-059063-index.htm |
| 2020-05-12 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 525.00 | 17.16 | 9,009.00 | 25,958.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029024/0001209191-20-029024-index.htm |
| 2019-05-08 | STEVE ASELAGE | Director | Buy | 2,000.00 | 259,642.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029151/0001209191-19-029151-index.htm | ||
| 2018-12-21 | STEVE ASELAGE | Chief Executive Officer | Sell | 900.00 | 22.35 | 20,111.04 | 259,772.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118064022/0001209191-18-064022-index.htm |
| 2020-07-28 | Noah L. Rosenberg | Chief Medical Officer | Sell | 870.00 | 20.49 | 17,826.30 | 26,055.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120044098/0001209191-20-044098-index.htm |
| 2018-12-21 | STEVE ASELAGE | Chief Executive Officer | Sell | 5,288.00 | 21.69 | 114,718.40 | 260,672.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118064022/0001209191-18-064022-index.htm |
| 2020-03-05 | STEVE ASELAGE | Director | Buy | 12,250.00 | 260,716.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120017537/0001209191-20-017537-index.htm | ||
| 2018-11-09 | STEVE ASELAGE | Chief Executive Officer | Buy | 18,500.00 | 264,383.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118058647/0001209191-18-058647-index.htm | ||
| 2020-05-11 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 525.00 | 14.95 | 7,848.75 | 26,483.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029024/0001209191-20-029024-index.htm |
| 2020-03-05 | Laura Clague | Chief Financial Officer | Buy | 4,000.00 | 26,500.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120017539/0001209191-20-017539-index.htm | ||
| 2018-12-20 | STEVE ASELAGE | Chief Executive Officer | Sell | 6,188.00 | 21.97 | 135,958.40 | 265,960.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118064022/0001209191-18-064022-index.htm |
| 2020-05-12 | Noah L. Rosenberg | Chief Medical Officer | Sell | 527.00 | 16.98 | 8,950.73 | 26,728.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120029021/0001209191-20-029021-index.htm |
| 2020-02-14 | WILLIAM E. ROTE | Senior Vice President, R&D | Sell | 1,250.00 | 16.72 | 20,900.00 | 26,896.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120010482/0001209191-20-010482-index.htm |
| 2020-09-22 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 1,500.00 | 18.59 | 27,885.00 | 26,931.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051613/0001209191-20-051613-index.htm |
| 2019-05-16 | Neil F. McFarlane | Chief Operating Officer | Sell | 984.00 | 18.71 | 18,410.64 | 26,988.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030661/0001209191-19-030661-index.htm |
| 2020-01-31 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Buy | 9,000.00 | 27,008.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120005903/0001209191-20-005903-index.htm | ||
| 2020-03-10 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Sell | 3,500.00 | 15.02 | 52,570.00 | 27,008.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120018648/0001209191-20-018648-index.htm |
| 2020-09-18 | WILLIAM E. ROTE | Senior Vice President, R&D | Buy | 3,000.00 | 27,086.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051615/0001209191-20-051615-index.htm | ||
| 2020-01-31 | WILLIAM E. ROTE | Senior Vice President, R&D | Buy | 9,000.00 | 27,185.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120005905/0001209191-20-005905-index.htm | ||
| 2018-12-18 | STEVE ASELAGE | Chief Executive Officer | Buy | 20,625.00 | 272,148.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118063772/0001209191-18-063772-index.htm | ||
| 2020-03-05 | Noah L. Rosenberg | Chief Medical Officer | Sell | 1,790.00 | 15.36 | 27,487.24 | 27,255.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120017538/0001209191-20-017538-index.htm |
| 2020-09-23 | Noah L. Rosenberg | Chief Medical Officer | Sell | 750.00 | 18.48 | 13,860.00 | 27,555.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051734/0001209191-20-051734-index.htm |
| 2019-05-15 | Neil F. McFarlane | Chief Operating Officer | Sell | 984.00 | 17.78 | 17,495.52 | 27,972.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030661/0001209191-19-030661-index.htm |
| 2020-09-22 | Noah L. Rosenberg | Chief Medical Officer | Sell | 750.00 | 18.59 | 13,942.50 | 28,305.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051614/0001209191-20-051614-index.htm |
| 2020-09-18 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Buy | 3,000.00 | 28,431.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051613/0001209191-20-051613-index.htm | ||
| 2018-11-14 | Neil F. McFarlane | Chief Operating Officer | Sell | 1,000.00 | 24.64 | 24,643.50 | 28,476.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059067/0001209191-18-059067-index.htm |
| 2020-03-05 | WILLIAM E. ROTE | Senior Vice President, R&D | Buy | 3,250.00 | 28,896.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120017541/0001209191-20-017541-index.htm | ||
| 2018-12-20 | Neil F. McFarlane | Chief Operating Officer | Sell | 6,404.00 | 22.56 | 144,451.83 | 28,956.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118064023/0001209191-18-064023-index.htm |
| 2019-05-08 | JOHN W KOZARICH | Director | Buy | 2,000.00 | 29,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029154/0001209191-19-029154-index.htm | ||
| 2019-05-08 | Timothy P Coughlin | Director | Buy | 2,000.00 | 29,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029153/0001209191-19-029153-index.htm | ||
| 2020-03-05 | Noah L. Rosenberg | Chief Medical Officer | Buy | 5,000.00 | 29,045.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120017538/0001209191-20-017538-index.htm | ||
| 2020-09-18 | Noah L. Rosenberg | Chief Medical Officer | Buy | 3,000.00 | 29,055.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051614/0001209191-20-051614-index.htm | ||
| 2018-11-14 | Neil F. McFarlane | Chief Operating Officer | Sell | 9,000.00 | 23.63 | 212,670.90 | 29,476.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118059067/0001209191-18-059067-index.htm |
| 2020-03-05 | ELIZABETH E REED | SVP, GC & Corporate Secretary | Buy | 3,500.00 | 30,508.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120017540/0001209191-20-017540-index.htm | ||
| 2019-05-08 | GARY A LYONS | Director | Buy | 2,000.00 | 31,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029155/0001209191-19-029155-index.htm | ||
| 2020-05-15 | TIMOTHY COUGHLIN | Director | Buy | 3,000.00 | 32,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030746/0001209191-20-030746-index.htm | ||
| 2020-05-15 | GARY A LYONS | Director | Buy | 3,000.00 | 34,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030747/0001209191-20-030747-index.htm | ||
| 2019-05-13 | Sandra Poole | Director | Buy | 3,500.00 | 3,500.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119030178/0001209191-19-030178-index.htm | ||
| 2019-10-01 | Peter Heerma | Chief Commercial Officer | Buy | 35,000.00 | 35,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119051975/0001209191-19-051975-index.htm | ||
| 2018-12-20 | Neil F. McFarlane | Chief Operating Officer | Sell | 4,721.00 | 22.00 | 103,881.36 | 35,360.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118064023/0001209191-18-064023-index.htm |
| 2018-11-09 | Neil F. McFarlane | Chief Operating Officer | Buy | 10,000.00 | 38,476.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118058649/0001209191-18-058649-index.htm | ||
| 2018-12-18 | Neil F. McFarlane | Chief Operating Officer | Buy | 11,125.00 | 40,081.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919118063774/0001209191-18-063774-index.htm | ||
| 2020-10-05 | Peter Heerma | Chief Commercial Officer | Sell | 2,188.00 | 19.35 | 42,337.80 | 42,329.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120053925/0001209191-20-053925-index.htm |
| 2020-01-08 | Eric M Dube | Chief Executive Officer | Sell | 3,750.00 | 15.14 | 56,775.00 | 42,500.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120002631/0001209191-20-002631-index.htm |
| 2020-01-31 | Peter Heerma | Chief Commercial Officer | Buy | 9,000.00 | 44,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120005901/0001209191-20-005901-index.htm | ||
| 2020-10-02 | Peter Heerma | Chief Commercial Officer | Sell | 2,188.00 | 18.90 | 41,353.20 | 44,517.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120053925/0001209191-20-053925-index.htm |
| 2020-01-07 | Eric M Dube | Chief Executive Officer | Sell | 3,750.00 | 13.94 | 52,275.00 | 46,250.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120002631/0001209191-20-002631-index.htm |
| 2019-01-04 | Eric M Dube | Chief Executive Officer | Buy | 50,000.00 | 50,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119002858/0001209191-19-002858-index.htm | ||
| 2020-04-08 | Suzanne Louise Bruhn | Director | Buy | 5,250.00 | 5,250.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120024096/0001209191-20-024096-index.htm | ||
| 2019-05-08 | Jeffrey A Meckler | Director | Buy | 2,000.00 | 61,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029156/0001209191-19-029156-index.htm | ||
| 2020-05-15 | Jeffrey A Meckler | Director | Buy | 3,000.00 | 64,000.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030748/0001209191-20-030748-index.htm | ||
| 2020-05-15 | Sandra Poole | Director | Buy | 3,000.00 | 6,500.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120030745/0001209191-20-030745-index.htm | ||
| 2020-01-31 | Eric M Dube | Chief Executive Officer | Buy | 35,000.00 | 77,500.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120005899/0001209191-20-005899-index.htm | ||
| 2019-05-08 | John A Orwin | Director | Buy | 2,000.00 | 8,875.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029157/0001209191-19-029157-index.htm | ||
| 2019-05-08 | Ron Squarer | Director | Buy | 2,000.00 | 8,875.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919119029159/0001209191-19-029159-index.htm | ||
| 2020-09-21 | Eric M Dube | Chief Executive Officer | Sell | 1,565.00 | 19.29 | 30,186.03 | 94,695.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051611/0001209191-20-051611-index.htm |
| 2020-09-21 | Eric M Dube | Chief Executive Officer | Sell | 9,240.00 | 19.28 | 178,133.34 | 96,260.00 | https://www.sec.gov/Archives/edgar/data/1438533/000120919120051611/0001209191-20-051611-index.htm |